Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Murepavadin plus ertapenem versus anti-pseudomonal beta-lactam therapy for nosocomial pneumonia due to Pseudomonas aeruginosa
2018-001159-11Phase 3Completed
- Sponsor
- Polyphor
- Start
- Oct 2018
- Modality
- Small Molecules, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of murepavadin and ertapenem in hospital-acquired pneumonia (HAP) and Pseudomonas pneumonia (2 arms), sponsored by Polyphor. Primary endpoint: 28-day all-cause mortality in micro-MITT population. Started Oct 2018; status: completed.
02
Drugs
murepavadinertapenem
03
Conditions
hospital-acquired pneumonia (HAP)Pseudomonas pneumonia
Beyond the preview
Go deeper on 2018-001159-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001159-11.